Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Wolfgang Miesbach: Breakthrough in Haemophilia B Treatment
Wolfgang Miesbach/LinkedIn
Aug 1, 2025, 16:51

Wolfgang Miesbach: Breakthrough in Haemophilia B Treatment

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a proud post on LinkedIn:

”Breakthrough in Haemophilia B Treatment: First-Ever Engineered B Cell Medicine Enters Clinical Trial. Be Biopharma has reached a historic milestone by dosing the first participant in their BeCoMe-9 Phase 1/2 trial of BE-101 – the world’s first Engineered B Cell Medicine (BCM) for haemophilia B.

This revolutionary approach may represent a paradigm shift from traditional gene therapy, offering unique advantages that could transform treatment for the 40,000 people living with this bleeding disorder globally.

What Makes BE-101 Different?

Unlike AAV-based gene therapies that deliver genes directly to the liver, BE-101 uses precision CRISPR/Cas9 gene editing to engineer the patient’s own B cells ex vivo to produce Factor IX.

These modified cells then function as living “protein factories” that can potentially:

  • Produce therapeutic proteins for decades (B cells naturally live 10+ years)
  • Be re-dosed and titrated as needed
  • Engraft without toxic preconditioning unlike other cellular therapies

Current AAV-based haemophilia B gene therapies, while successful, face several challenges:

Known AAV Limitations:
– One-time only treatment due to neutralizing antibodies
– Pre-existing immunity excludes 40-60% of patients from treatment
– Declining efficacy over time – Factor IX levels can drop significantly
– Liver toxicity requiring immunosuppression in 17-89% of patients
– Limited cargo capacity restricting therapeutic options
– Only investigated and approved for the adult population

Potential BCM Advantages:
– Re-dosable and titratable – can adjust treatment as needed
– No preconditioning required – reduces treatment burden
– Sustained production – B cells can produce proteins for decades
– Potentially broader patient eligibility – not limited by AAV immunity or the age of the patients

Challenges Ahead:
While revolutionary, BCM therapy faces its own hurdles:

  • Complex manufacturing requiring sophisticated cell culture and gene editing
  • Unknown long-term durability compared to 13+ year AAV data
  • Potential immune responses to engineered cells
  • Manufacturing scalability for broader patient access.”

Wolfgang Miesbach gives a detailed review on BeCoMe-9 ,be sure to read the full article here.

Wolfgang Miesbach: Breakthrough in Haemophilia B Treatment

Stay updated with the latest scientific advancements in the field of hemophilia with Hemostasis Today.

Be Biopharma BE101 BeCoMe-9 BioSpace CRISPR Gene therapy haemophilia Health Hematology Hemostasis Today Joanne Smith-Farrell Medicine Wolfgang Miesbach
NewsFeed